Forgive me, but I'm going to have to interrupt you. I have a very limited amount of time and I have a lot of questions written down.
Can you tell me why in your decision-making in the recommendations....? I'll give you a specific example. In the case of Spinraza, you gave criteria for the recommendation that fall within the kind of jurisdiction you've laid out. Why is it that you look at price instead of just efficacy? It seems to me that price is a question for the PMPRB when it's a patented medicine, and then for the pCPA during drug negotiations, not for the people who do an assessment or the management and a review of whether this is efficacious for patients or not.
Why is price being considered? In the case of Spinraza, the recommendation was “substantial reduction in price”. That doesn't seem to have anything to do with whether this works for patients or not.